Abstract:Background Arsenic trioxide [ATO, inorganic arsenite (iAs III ) in solution] plays an important role in the treatment of acute promyelocytic leukemia (APL). However, the long-term adverse effects (AEs) and the retention of arsenic among APL patients are rarely reported. In this study, we focused on arsenic methylation metabolism and its relationship with chronic hepatic toxicity, as we previously reported, among APL patients who had finished the treatment of ATO. Methods A total of 112 de novo APL patients who had completed the ATO-containing treatment were enrolled in the study. Arsenic species [iAs III , inorganic arsenate (iAs V ), and their organic metabolites, monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)] in patients’ plasma, urine, hair and nails were detected by high-performance liquid chromatography combined with inductively coupled plasma mass spectrometry (HPLC-ICP-MS). Eighteen single nucleotide polymorphisms (SNPs) of the arsenic (+ 3 oxidative state) methylation transferase ( AS3MT ) gene, which was known as the main catalyzer for arsenic methylation, were tested with the polymerase chain reaction method. Results The study showed the metabolic pattern of arsenic in APL patients undergoing and after the treatment of ATO, in terms of total arsenic (TAs) and four species of arsenic. TAs decreased to normal after 6 months since cessation of ATO. But the arsenic speciation demonstrated significantly higher portion of iAs III in patient’s urine (40.08% vs. 1.94%, P < 0.001), hair (29.25% vs. 13.29%, P = 0.002) and nails (30.21% vs. 13.64%, P = 0.003) than the healthy controls’, indicating a decreased capacity of arsenic methylation metabolism after the treatment of ATO. Urine primary methylation index (PMI) was significantly lower in patients with both chronic liver dysfunction (0.14 vs. 0.28, P = 0.047) and hepatic steatosis (0.19 vs. 0.3, P = 0.027), suggesting that insufficient methylation of arsenic might be related to chronic liver disorders. Two SNPs (A9749G and A27215G) of the AS3MT gene were associated with impaired urine secondary methylation index (SMI). Conclusions The long-term follow-up of arsenic speciation indicated a decreased arsenic methylation metabolism and a probable relationship with chronic hepatic disorders among APL patients after the cessation of ATO. Urine PMI could be a monitoring index for chronic AEs of ATO, and the SNPs of AS3MT gene should be considered when determining the dosage of ATO.

Arsenic Methylation Metabolism and Liver Injury of Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.

Importance of Monitoring Arsenic Methylation Metabolism in Acute Promyelocytic Leukemia Patients Receiving the Treatment of Arsenic Trioxide.

Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide

Hepatotoxicity from Arsenic Trioxide for Pediatric Acute Promyelocytic Leukemia

Relationship between Changes of Arsenic Levels in Urine and Side Effects among Leukemia Patients Treated with Trioxide Arsenic

Pharmacokinetic Characteristics, Tissue Bioaccumulation and Toxicity Profiles of Oral Arsenic Trioxide in Rats: Implications for the Treatment and Risk Assessment of Acute Promyelocytic Leukemia

Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide

[Pharmacokinetics of Intravenous Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia].

Use Of Arsenic Trioxide (As2o3) In The Treatment Of Acute Promyelocytic Leukemia (Ape) .2. Clinical Efficacy And Pharmacokinetics In Relapsed Patients

Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Studies on Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients.

Influence of AS3MT Polymorphisms on Arsenic Metabolism and Liver Injury in APL Patients Treated with Arsenic Trioxide

Characteristics and Clinical Influence Factors of Arsenic Species in Plasma and Their Role of Arsenic Species As Predictors for Clinical Efficacy in Acute Promyelocytic Leukemia (APL) Patients Treated with Arsenic Trioxide

Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies

Polymorphisms in Arsenic (+ 3 Oxidation State) Methyltransferase (AS3MT) Predict the Occurrence of Hyperleukocytosis and Arsenic Metabolism in APL Patients Treated with As2O3.

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Role of Arsenic (+3 Oxidation State) Methyltransferase in Arsenic Mediated APL Treatment: an in Vitro Investigation.

Studies on the Clinical Efficacy and Pharmacokinetics of Low-Dose Arsenic Trioxide in the Treatment of Relapsed Acute Promyelocytic Leukemia: a Comparison with Conventional Dosage.

Trivalent Methylated Arsenic Metabolites Induce Apoptosis in Human Myeloid Leukemic HL-60 Cells Through Generation of Reactive Oxygen Species

The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients